JPY 8530.0
(-0.92%)
Year | Net Income | Net Income Growth |
---|---|---|
2023 | 121.61 Billion JPY | -9.18% |
2022 | 133.9 Billion JPY | 6.73% |
2021 | 125.46 Billion JPY | -15.31% |
2020 | 148.13 Billion JPY | 16.5% |
2019 | 127.15 Billion JPY | 54.14% |
2018 | 82.49 Billion JPY | -26.67% |
2017 | 112.49 Billion JPY | 21.53% |
2016 | 92.56 Billion JPY | 10.08% |
2015 | 84.08 Billion JPY | -44.4% |
2014 | 151.23 Billion JPY | 0.16% |
2013 | 150.98 Billion JPY | 23.33% |
2012 | 122.42 Billion JPY | 32.82% |
2011 | 92.17 Billion JPY | 13.79% |
2010 | 81 Billion JPY | 20.1% |
2009 | 67.44 Billion JPY | 43.24% |
2008 | 47.08 Billion JPY | 0.0% |
Year | Net Income | Net Income Growth |
---|---|---|
2024 Q3 | 83.87 Billion JPY | 175.74% |
2024 Q2 | 30.41 Billion JPY | -60.69% |
2024 Q1 | 77.37 Billion JPY | 292.97% |
2023 Q2 | 41.16 Billion JPY | -32.99% |
2023 FY | 121.61 Billion JPY | -9.18% |
2023 Q1 | 61.43 Billion JPY | 167.21% |
2023 Q4 | -40.09 Billion JPY | -167.83% |
2023 Q3 | 59.11 Billion JPY | 43.62% |
2022 FY | 133.9 Billion JPY | 6.73% |
2022 Q1 | 23.25 Billion JPY | 2062.03% |
2022 Q2 | 46.52 Billion JPY | 100.09% |
2022 Q4 | 22.98 Billion JPY | -44.29% |
2022 Q3 | 41.26 Billion JPY | -11.3% |
2021 FY | 125.46 Billion JPY | -15.31% |
2021 Q1 | 44.68 Billion JPY | 119.34% |
2021 Q2 | 46.72 Billion JPY | 4.57% |
2021 Q3 | 35.24 Billion JPY | -24.58% |
2021 Q4 | -1.18 Billion JPY | -103.36% |
2020 Q1 | 37.71 Billion JPY | 141.24% |
2020 Q4 | 20.37 Billion JPY | -50.26% |
2020 Q3 | 40.95 Billion JPY | -16.59% |
2020 Q2 | 49.1 Billion JPY | 30.2% |
2020 FY | 148.13 Billion JPY | 16.5% |
2019 Q3 | 43.75 Billion JPY | -9.99% |
2019 Q1 | 19.15 Billion JPY | 297.84% |
2019 FY | 127.15 Billion JPY | 54.14% |
2019 Q4 | 15.63 Billion JPY | -64.27% |
2019 Q2 | 48.61 Billion JPY | 153.82% |
2018 Q4 | 4.81 Billion JPY | -65.12% |
2018 FY | 82.49 Billion JPY | -26.67% |
2018 Q1 | 22.72 Billion JPY | -42.36% |
2018 Q2 | 41.57 Billion JPY | 82.94% |
2018 Q3 | 13.8 Billion JPY | -66.81% |
2017 Q3 | 30.63 Billion JPY | 43.07% |
2017 FY | 112.49 Billion JPY | 21.53% |
2017 Q1 | 21.01 Billion JPY | 969.31% |
2017 Q2 | 21.41 Billion JPY | 1.91% |
2017 Q4 | 39.42 Billion JPY | 28.69% |
2016 FY | 92.56 Billion JPY | 10.08% |
2016 Q4 | 1.96 Billion JPY | -96.61% |
2016 Q3 | 58.02 Billion JPY | 109.05% |
2016 Q2 | 27.75 Billion JPY | 26.98% |
2016 Q1 | 21.85 Billion JPY | 214.78% |
2015 FY | 84.08 Billion JPY | -44.4% |
2015 Q1 | 33.96 Billion JPY | 0.0% |
2015 Q2 | 35.51 Billion JPY | 4.58% |
2015 Q3 | 33.65 Billion JPY | -5.23% |
2015 Q4 | -19.04 Billion JPY | -156.58% |
2014 Q2 | 45.24 Billion JPY | 454.62% |
2014 FY | 151.23 Billion JPY | 0.16% |
2014 Q4 | - JPY | -100.0% |
2014 Q3 | 54.25 Billion JPY | 19.92% |
2014 Q1 | 8.15 Billion JPY | -85.38% |
2013 Q4 | 55.81 Billion JPY | 17.97% |
2013 FY | 150.98 Billion JPY | 23.33% |
2013 Q1 | 31.23 Billion JPY | 9.42% |
2013 Q2 | 39.7 Billion JPY | 27.12% |
2013 Q3 | 47.31 Billion JPY | 19.17% |
2012 Q2 | 31.92 Billion JPY | 801.95% |
2012 Q3 | 30.72 Billion JPY | -3.77% |
2012 Q4 | 28.54 Billion JPY | -7.1% |
2012 FY | 122.42 Billion JPY | 32.82% |
2012 Q1 | 3.54 Billion JPY | -88.74% |
2011 Q2 | 31.15 Billion JPY | 168.79% |
2011 FY | 92.17 Billion JPY | 13.79% |
2011 Q4 | 31.43 Billion JPY | 20.68% |
2011 Q1 | 11.59 Billion JPY | -28.55% |
2011 Q3 | 26.04 Billion JPY | -16.4% |
2010 Q3 | 31.48 Billion JPY | 48.62% |
2010 Q1 | 1.93 Billion JPY | -90.41% |
2010 FY | 81 Billion JPY | 20.1% |
2010 Q4 | 16.22 Billion JPY | -48.48% |
2010 Q2 | 21.18 Billion JPY | 992.57% |
2009 Q3 | 25.55 Billion JPY | 29.53% |
2009 Q2 | 19.73 Billion JPY | 0.0% |
2009 Q4 | 20.21 Billion JPY | -20.91% |
2009 FY | 67.44 Billion JPY | 43.24% |
2008 FY | 47.08 Billion JPY | 0.0% |
Name | Net Income | Net Income Difference |
---|---|---|
Kyowa Kirin Co., Ltd. | 81.18 Billion JPY | -49.796% |
Astellas Pharma Inc. | 17.04 Billion JPY | -613.5% |
Chugai Pharmaceutical Co., Ltd. | 325.47 Billion JPY | 62.634% |
Ono Pharmaceutical Co., Ltd. | 127.97 Billion JPY | 4.97% |
Santen Pharmaceutical Co., Ltd. | 26.64 Billion JPY | -356.482% |
JCR Pharmaceuticals Co., Ltd. | 5.5 Billion JPY | -2108.389% |
Daiichi Sankyo Company, Limited | 200.73 Billion JPY | 39.413% |
Perseus Proteomics Inc. | -1.1 Billion JPY | 11111.354% |